Drug Makers Shifting Towards Targeted Cancer Drugs
The continuing shift away from one-size-fits-all cancer treatments will be on display this week when a medical society releases clinical data for drugs that target unique molecular features of cancer cells.
PFE
+1.61%
JNJ
+0.31%
Pfizer Inc. , GlaxoSmithKline PLC (GSK, GSK.LN) and Johnson & Johnson are among those whose drugs will be highlighted when the American Society of Clinical Oncology on Wednesday releases summaries of more than 4,500 cancer studies, two weeks ahead of ASCO's annual scientific meeting.
Read the full story:
Source: Market Watch (The Wall Street Journal)
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025